A comparative study of QT prolongation with serotonin reuptake inhibitors

BackgroundQT interval prolongations were described with citalopram and escitalopram. However, the effects of the other serotonin reuptake inhibitors (SRIs) remained discussed. In order to identify a putative signal with other SRIs, the present study investigates the reports of QT interval prolongation with SRIs in two pharmacovigilance databases (PVDB).MethodsTwo kinds of investigations were performed: (1) a comparative study in VigiBase®, the WHO PVDB, where notifications of QT prolongation with six SRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) were selected. Cases with overdose or pregnancy were excluded. The relationship between the “suspected” SRI and occurrence of QT prolongation was assessed by calculating reporting odds ratio (ROR) in a case/non-case design. (2) A descriptive study of QT prolongation reports with citalopram and escitalopram in the French FPVD.ResultsIn VigiBase®, 855 notifications were identified (mean age 56.2 years, mainly women 73%). Among them, 172 (20.1%) were associated to escitalopram; 299 (35.0%), to citalopram; 186 (21.8%), to fluoxetine; 94 (11.0%), to sertraline; 66 (7.7%), to paroxetine; and 38 (4.4%) to fluvoxamine. A significant ROR value (higher than 1) was only found for citalopram (3.35 CI95% [2.90–3.87]) or escitalopram (2.50 [2.11–2.95]). In the FPVD, eight reports of QT prolongation were found with citalopram and 27 with escitalopram, mainly in women (77.1%) with a mean age of 73.2 years. In 23 cases (66%), SRIs were associated with other suspected drugs, mainly cardiotropic or psychotropic ones. Hypokalemia was associated in six patients.ConclusionThis study, performed in real conditions of life, shows a clear signal of QT prolongation with only two SRIs, citalopram and escitalopram, indicating that QT prolongation is not a SRI class effect.

[1]  J. Deakin,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines , 2000 .

[2]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[3]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[4]  S. Hägg,et al.  Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance database , 2008, Pharmacoepidemiology and drug safety.

[5]  A Bate,et al.  The application of knowledge discovery in databases to post‐marketing drug safety: example of the WHO database , 2008, Fundamental & clinical pharmacology.

[6]  M. Lapeyre-Mestre,et al.  QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone‐treated patients in France , 2011, Fundamental & clinical pharmacology.

[7]  J. Hippisley-Cox,et al.  Antidepressant use and risk of adverse outcomes in older people: population based cohort study , 2011, BMJ : British Medical Journal.

[8]  Maryse Lapeyre-Mestre,et al.  Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. , 2011, British journal of clinical pharmacology.

[9]  Charles E. Leonard,et al.  Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia , 2011, Pharmacoepidemiology and drug safety.

[10]  Jørgen K. Kanters,et al.  Antidepressant Use and Risk of Out‐of‐Hospital Cardiac Arrest: A Nationwide Case–Time–Control Study , 2012, Clinical pharmacology and therapeutics.

[11]  K. Zivin,et al.  Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. , 2013, The American journal of psychiatry.

[12]  M. Fava,et al.  QT interval and antidepressant use: a cross sectional study of electronic health records , 2013, BMJ.

[13]  Jolene R. Bostwick,et al.  A Comparison of the Risk of QT Prolongation Among SSRIs , 2013, The Annals of pharmacotherapy.

[14]  D. Shah,et al.  Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. , 2013, The American journal of psychiatry.

[15]  J. Ruskin,et al.  Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. , 2014, The Journal of clinical psychiatry.

[16]  A. Pathak,et al.  Évaluation de l’intervalle QT sous antidépresseurs inhibiteurs de la recapture de la sérotonine : étude des pratiques dans un service hospitalo-universitaire de psychiatrie , 2015 .

[17]  [Measurement of QT interval and serotoninergic reuptake inhibitor antidepressants: A study in a university psychiatric hospital]. , 2015, L'Encephale.

[18]  A. Hofman,et al.  Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. , 2015, British journal of clinical pharmacology.

[19]  R. Tampi,et al.  Citalopram, QTc Prolongation, and Torsades de Pointes. , 2015, Psychosomatics.

[20]  T. Vial.  French pharmacovigilance: Missions, organization and perspectives. , 2016, Therapie.

[21]  F. Haramburu,et al.  Causality assessment in pharmacovigilance: The French method and its successive updates. , 2016, Therapie.

[22]  D. Nelson,et al.  Outcomes of Citalopram Dosage Risk Mitigation in a Veteran Population. , 2016, The American journal of psychiatry.

[23]  A. Pariente,et al.  PHARMACOVIGILANCE Pharmacoepidemiology and its input to pharmacovigilance , 2016 .

[24]  N. Richard,et al.  Dispositif pharmacoépidémiologique de surveillance des substances psychoactives : intérêts du programme national OPPIDUM du Réseau français d’addictovigilance , 2017 .

[25]  N. Richard,et al.  [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network]. , 2017, Therapie.